A fixed-dose combination (FDC) of a thienodiazepine derivative (Etizolam) and a non-selective beta-adrenergic blocker (Propranolol). Etizolam acts as a short-acting anxiolytic, sedative, and muscle relaxant by potentiating GABAergic neurotransmission. Propranolol mitigates the peripheral somatic symptoms of anxiety (e.g., palpitations, tremors) by blocking beta-1 and beta-2 adrenergic receptors. This combination targets both the psychological and physiological components of anxiety disorders. Its use is controversial and heavily regulated in India due to significant abuse potential and dependence liability of Etizolam.
Adult: One tablet (Etizolam 0.5mg + Propranolol 40mg) once or twice daily. MUST be the lowest effective dose for the shortest possible duration, not exceeding 2-4 weeks. Initiate with half a tablet (0.25mg+20mg) in elderly or debilitated patients.
Note: Take orally with or without food. Food may slow absorption but does not significantly affect overall bioavailability. Take at the same time(s) each day. Do not crush or chew. DO NOT SUDDENLY DISCONTINUE; taper dose gradually under medical supervision to avoid withdrawal symptoms (anxiety, insomnia, palpitations, rebound hypertension).
The combination exerts a dual mechanism: central anxiolysis and peripheral beta-blockade. Etizolam binds to the benzodiazepine binding site on the GABA-A receptor complex, increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and CNS depression. Propranolol competitively antagonizes catecholamine effects at beta-1 (cardiac) and beta-2 (vascular, bronchial, metabolic) adrenergic receptors, reducing heart rate, myocardial contractility, blood pressure, and tremor.
Pregnancy: Category D (Etizolam - based on benzodiazepine data) / Category C (Propranolol). CONTRANDICATED, especially in first trimester. Risk of congenital malformations (cleft palate, cardiac defects), neonatal flaccidity, withdrawal symptoms, and fetal bradycardia. Use only if potential benefit justifies extreme fetal risk.
Driving: STRONGLY NOT ADVISED. The drug causes drowsiness, dizziness, and impaired judgment and motor coordination. Patients should not drive or operate machinery until they know how the drug affects them.
| Other CNS Depressants (Alcohol, Opioids, Barbiturates, other Benzodiazepines) | Profoundly increased sedation, respiratory depression, risk of death | Major |
| Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Markedly increased Etizolam levels, leading to excessive sedation and toxicity | Major |
| CYP2D6 Inhibitors (Fluoxetine, Paroxetine, Quinidine) | Increased Propranolol levels, enhanced bradycardia and hypotension | Moderate |
| Calcium Channel Blockers (Verapamil, Diltiazem) | Additive negative inotropic and chronotropic effects; severe bradycardia and heart block risk | Major |
| Clonidine | Abrupt withdrawal of either can cause severe rebound hypertension. Propranolol can potentiate rebound hypertension after clonidine withdrawal. | Major |
| Insulin, Oral Hypoglycemics | Propranolol masks tachycardia from hypoglycemia and may impair glucose recovery; may also potentiate hypoglycemia. | Moderate |
| NSAIDs (e.g., Ibuprofen, Naproxen) | May antagonize the antihypertensive effect of Propranolol. | Moderate |
| Theophylline | Propranolol may antagonize bronchodilator effects; Etizolam may have additive CNS effects. | Moderate |
Same composition (Etizolam (0.5mg) + Propranolol (40mg)), different brands: